Trials / Conditions / Lymphoma, Non-Hodgkin's

Lymphoma, Non-Hodgkin's

16 registered clinical trials studyying Lymphoma, Non-Hodgkin's — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers NCT07226843	Eli Lilly and Company	Phase 1
Active Not Recruiting	Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multip NCT04756726	C4 Therapeutics, Inc.	Phase 1
Completed	Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02750670	University Health Network, Toronto	Phase 2
Terminated	Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma NCT02518750	St. Jude Children's Research Hospital	Phase 2
Terminated	Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia NCT02473523	St. Jude Children's Research Hospital	N/A
Completed	Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma NCT01733238	Sierra Oncology LLC - a GSK company	Phase 2
Terminated	Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma NCT00651443	Biogen	Phase 1
Terminated	Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) NCT00384150	Biogen	Phase 3
Terminated	In-Vivo Activated T-Cell Depletion to Prevent GVHD NCT00594308	Indiana University	N/A
Terminated	A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) NCT00363636	Biogen	Phase 3
Completed	A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma NCT00413036	Celgene	Phase 2
Terminated	AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable NCT00395967	Genzyme, a Sanofi Company	Phase 2
Completed	Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma NCT00161590	Weill Medical College of Cornell University	Phase 1
Terminated	Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma NCT00141700	University of Michigan Rogel Cancer Center	Phase 2
Completed	Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma NCT00143871	University of Michigan Rogel Cancer Center	Phase 2
Terminated	Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood NCT00143884	University of Michigan Rogel Cancer Center	Phase 2